Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infections--the Fluco French cohort.

BACKGROUND: The emergence of novel A(H1N1)pdm2009 virus threatened to lead to frequent severe manifestations. OBJECTIVES: To describe the clinical, virological, and biological characteristics of the disease and identify the factors associated with severe presentations. STUDY DESIGN: This prospective multicenter study recruited consecutive hospitalized patients with confirmed A(H1N1)pdm2009 disease. Clinical, virological and biological assessments were carried out at inclusion and 30 days post-inclusion. Disease manifestations were assessed by an adjudication committee using pre-identified definitions of complications and severity scores. RESULTS: The study analyzed from November 30th, 2009 to February 8th, 2010, 40 hospitalized patients, 21 children and 19 adults. Eighteen (45%) were considered to have severe presentations. Except age, main characteristics in children and adults did not differ. The majority (18/21) of children and all adults had a respiratory presentation; extra-respiratory manifestations tended to be more frequent in children (12 vs. 6, P=0.10). Two children against 5 adults presented acute respiratory distress syndrome (ARDS, P=0.23), but more children suffered respiratory failure (7 vs. 1, P=0.046) without ARDS. At day 30, one death had occurred in each group. The main factor associated with non-severe presentation was an early (<48 h) implementation of oseltamivir treatment (P=0.038). CONCLUSIONS: Although the study failed to achieve its main objective, due mainly to the difficulty of carrying a study of this nature in the midst of a pandemic, it allowed the description of a panel of unusual and complicated forms and confirmed the added value of early oseltamivir treatment in limiting severity in hospitalized children and adults.

[Vaccination rate of premature infants at 6 and 24 months of age: a pilot study]. / Couverture vaccinale des grands prématurés à 6 mois et à 2 ans: étude pilote.

UNLABELLED: There are few data examining the vaccine practices for 0- to 24-month-old premature infants born before 33 GW. The aim of the study was to examine the vaccine coverage in this population according to the French schedule at 6 and 24 months. RESULTS: Eighty-seven infants were included in this regional prospective study. The immunization program began late and was initialized principally with DTPCoqHib (63%), usually after the 4th month. Fewer than one infant out of two (45%) had received three doses by 6 months of age. At 2 years of age, the coverage was 99% at 3 doses and decreased to 83% for 4 doses. For the MMR vaccine, the average age of administration was after 15 months, and 95% of infants had received one dose of MMR at 2 years of age. BCG coverage at 2 years of age was 94%, administered on average at 7 months. Forty-seven percent of the infants had received at least one dose of hepatitis B vaccine before 2 years of age, but only 31% had received two doses and a booster at 2 years of age. The adaptation of vaccination practices basically concerns the initial date of vaccination, but the immunization calendar is not recovered at 2 years of age. This should be taken into account for pertussis disease prevention in these young infants during the first 6 months of life, increasing the susceptibility period for this infectious disease. DISCUSSION AND CONCLUSION: The vaccine practices do not follow the postnatal chronological age of the premature baby according to the schedule recommended for full-term infants and vaccination is begun late. Based on the CSHPF vaccination recommendations, nearly 7 premature infants out of 10 have an incomplete immunization status for DTPCoqHib, hepatitis B, and ROR at 2 years of age. According to the pertussis coverage observed in premature infants, the new recommendations on vaccination of the newborn's care giver and family should be completed before the infant's discharge from the hospital using a new acellular vaccine for adult immunization. The initiation of an immunization program during hospitalization would be beneficial for premature babies still hospitalized after 2 months of age.

[Evaluation of the perinatal network professionals' integration: study about 653 professionals of AURORE network]. / Evaluation de l'intégration des professionnels au sein d'un réseau de périnatalité: enquête auprès de 653 professionnels du réseau AURORE.

OBJECTIVES: Evaluation of the AURORE perinatal network professionals' satisfaction and integration and identification of explanatory factors, three years after implementation. METHOD AND MATERIALS: Transversal study with postal questionnaire sent at 653 AURORE network perinatal professionals. RESULTS: Awareness and participation to network meetings were not associated with the geographic proximity of administrative headquarters (p=0.2) but with consciousness of network website and of network experts identified for each maternity (p<0.001). Patients management was estimated more easy for 92% of professionals. Network impact was evaluated as positive in professional practice (88.2%). Professionals integration were demonstrated by knowledge of network guidelines (94.8%) and their use (96%). CONCLUSION: AURORE perinatal network professionals, three years after implementation, were involved in network maternity. Their participation and interest for this organisation were associated with directs benefits they could get in facilitating their relationship with patients and other health professionals in each day practice.

[Evaluation of clinical practices: methods of data collection and information sources?]. / L'évaluation des pratiques cliniques: quels modes de recueil des données et à partir de quelles sources d'information?

OBJECTIVE: The aim of our study is to present the methods used to observe clinical practices, to evaluate their advantages and limits, and to specify the context in which they are preformed. METHODS: We conducted a bibliographical search on MEDLINE using key words, completed by an offline search. We selected articles published in French or English between 1985 and 2003. RESULTS: Thirty articles, of which 3 were reviews, as well as an additional 5 reports and 9 books, were selected. We distinguished direct or objective approaches to clinical practices as well as indirect or declarative approaches. We also noted whether the approach was individual with data collected from individual practitioners, or collective, with data coming from databases. Most methods of collecting data used medical records, often in the context of internal or external clinical audits or peer reviews. The other sources of data were self-administered questionnaires, written case simulations and simulated patients. Data was also extracted from previously existing databases: claims databases, registries and ad hoc databases. CONCLUSION: An objective individual approach insures the highest quality of information, but possible high costs can limit the use of this approach. It is necessary to continue researching the best means of collecting data on clinical practices, because of the obligation of each practitioner to evaluate individual clinical practices.

[Treatment of exacerbation of asthma: what are today's issues?]. / Traitement de la crise d'asthme: où sont aujourd'hui les enjeux?

During past decades, major progress has been accomplished in the management of acute asthma. Most recent recommendations include evidence-based rationale. The improved quality of clinical guidelines makes them efficient models for medical education. The pediatric pharmacopoeia provides a great variety of choices of drugs as well as for asthma medical devices. These innovations dramatically facilitated the medical management of asthmatic children, but they did not solve all problems. Physicians now use higher doses of salbutamol, but the early prescription of systemic glucocorticoids for moderate exacerbation of asthma is still underused, given the most recent clinical guidelines and meta-analysis. Furthermore, repeated emergency department visits to the wards and lack of primary care physician should systematically be appraised when evaluating severity, as they are both major risk factors for severe exacerbations, even though they are not considered in acute asthma severity scores. Finally, initiating (or reinforcing) patient education at the time of exacerbation also presents important challenges, as emergency visits are a favorable moment to commence the therapeutic education of the child and his family. Indeed, framing the controller medications and educating families about how to manage the disease and to improve their domestic environment are the genuine tools available for the prevention of asthma exacerbations, and particularly those most severe.

[Risk factors for amoxicillin-clavulanate-resistant Escherichia coli in ICU patients]. / Facteurs de risque d'infection à Escherichia coli résistant à l'amoxicilline-acide clavulanique en réanimation.

OBJECTIVE: To determine risk factors of infections with amoxicillin-clavulanate-resistant Escherichia coli in ICU patients. STUDY DESIGN: Prospective, consecutive sample survey study. PATIENTS: A consecutive series of 133 patients from whom culture results were positive for E. coli during their ICU stay. METHODS: Risk factors analysed included demographics, comorbid conditions, and antimicrobial drug exposure. Univariate and multivariate analysis were performed. RESULTS: Multivariate logistic regression analysis identified only one significant independent factor associated with the emergence of amoxicillin-clavulanate-resistant E. coli: prior use of amoxicillin (odds ratio: 5.45). CONCLUSION: Clinicians should avoid administering amoxicillin-clavulanate as empiric therapy for possible E. coli infection in patients that have recently been treated with amoxicillin.

[Risk factors for early bronchiolitis at asthma during childhood: case-control study of asthmatics aged 4 to 12 years]. / Antécédent de bronchiolite précoce et asthme du grand enfant: étude cas-témoins chez des asthmatiques de 4 à 12 ans.

UNLABELLED: The group of general paediatrics of the French Paediatrics Society conducted a case-control study in order to verify the link between the occurrence of an acute bronchiolitis early during the first year of life, more specifically during the first trimester, and asthma during later childhood. METHODS: Parents of 4-to-12-year-old children answered a questionnaire during a general paediatrics visit. Exposition was attested by a diagnosis of bronchiolitis mentioned on the personal health record of the child. Environmental factors and medical history, obtained from the parents and by checking the health record of the child, were studied using multivariate analysis. RESULTS: Nineteen paediatricians included 80 children with asthma and 160 controls. Fifty-four per cent of asthmatic children had a medical history of bronchiolitis during the first year of life versus 17% of control children (P < 0.001). Mean age of bronchiolitis occurrence was 6.6 months in both groups (P = 0.98). Multivariate analysis showed that occurrence of bronchiolitis during the first year of life was significantly more frequent in asthmatic children (P < 0.001, OR = 5.6, IC95 = [2.6-11.6]) but this effect was not observed during the first trimester of life. CONCLUSION: Bronchiolitis during the first year of life was significantly related to later asthma in 4-to-12-year-old children treated by general paediatricians. On the other hand, a very early bronchiolitis during the first trimester of life did not appear, in our set of data, as a contributive factor to explain asthma in later childhood.

Formation of isoprostanes in children with type IIa hypercholesterolemia.

F2-isoprostanes are stable lipid peroxidation products of arachidonic acid and their quantification provides a novel approach to the assessment of oxidative stress in vivo. F2-isoprostanes are present in increased amounts in adult hypercholesterolemia, but no data exist concerning children. We investigated urinary isoprostaglandin F2, type III production as an index of lipid peroxidation in 15 children presenting with type IIa hypercholesterolemia (serum total cholesterol, 290 [SD +/- 70] mg/dl; low-density lipoprotein cholesterol, 210 [SD +/- 90] mg/dl) compared with 15 sex- and age-paired control children (serum total cholesterol, 160 [SD +/- 20] mg/dl). Urinary levels of isoprostaglandin F2alpha type III were measured by gas chromatography mass spectrometry. Urinary concentrations did not differ significantly in hypercholesterolemic children compared with control children (84.7 [SD +/- 37] vs. 96 [SD +/- 35] pmol/mmol creatinine, respectively). No significant correlation was found with total cholesterol, low-density-lipoprotein and high-density-lipoprotein cholesterol, and apolipoprotein B and A1 serum levels. F2-isoprostane urinary levels in children with type IIa hypercholesterolemia do not differ from those of age- and sex-matched control children and are not correlated to blood lipid parameters, suggesting that hypercholesterolemia is not associated with increased lipid peroxidation in childhood.

High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial.

UNLABELLED: Inhaled albuterol is the most frequently used bronchodilator for acute wheezing, and nebulization is the standard mode of delivery in hospital setting. However, recent guidelines consider spacer devices as an easier to use, and cost-saving alternative and recommend the high-dose metered-dose inhaler bronchodilator. OBJECTIVE: To demonstrate clinical equivalence between a spacer device and a nebulizer for albuterol administration. DESIGN: Randomized, double-blind, parallel group equivalence trial. SETTING: Pediatric emergency wards at 2 tertiary teaching hospitals. PATIENTS: Sixty-four 12- to 60-month-old children with acute recurrent wheezing (32 per group). INTERVENTIONS: Albuterol was administered through the spacer device (50 microg/kg) or through the nebulizer (150 microg/kg) and repeated 3 times at 20-minute intervals. Parents completed a questionnaire. OUTCOME MEASURES: Pulmonary index, hospitalization, ease of use, acceptability, and pulse oximetry saturation. RESULTS: The 90% confidence interval of the difference between treatment groups for the median absolute changes in pulmonary index values between T0 and T60 was [-1; +1] and was included in the equivalence interval [-1.5; +1.5]. Clinical improvement increased with time. Less than 10% of the children (3 in each group) required hospitalization (2 in each group attributable to treatment failure). Parents considered administration of albuterol using the spacer device easier (94%) and better accepted by their children (62%). CONCLUSIONS: The efficacy of albuterol administered using the spacer device was equivalent to that of the nebulizer. Given its high tolerance, repeated 50-microg/kg doses of albuterol administered through the spacer device should be considered in hospital emergency departments as first-line therapy for wheezing.

Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma.

Pharmacokinetically guided administration of melphalan was investigated during a pilot study in patients with advanced ovarian adenocarcinoma. The schedule involved a fixed dose on day 1 (7.9 mg) followed by a second dose on day 2, calculated on the basis of pharmacokinetic data to achieve a target area under the concentration-time curve (AUC). 20 courses of intravenous melphalan were administered to 7 patients. AUC, standardised to 1 mg/m2, ranged between 4.3 and 8.9 (mg/l) min. In 12 fully evaluable courses, less than 15% deviation from the target AUC was found, showing that AUC monitoring was possible by means of the test dose. Pharmacodynamic effects showed a positive correlation with melphalan AUC. Myelosuppression appeared at 47 (mg/l) min and grade 3 or 4 haematological toxicities were observed in 4 cycles, associated with AUC values ranging between 86 and 112 (mg/l) min. Relative leucocyte decreases were well correlated with AUC values.